Cargando…

Effects of a sodium‐glucose cotransporter 2 inhibitor in nonalcoholic fatty liver disease complicated by diabetes mellitus: Preliminary prospective study based on serial liver biopsies

A prospective study based on serial liver biopsies was performed to investigate the efficacy of sodium‐glucose cotransporter 2 inhibitor for nonalcoholic fatty liver disease complicated with type 2 diabetes mellitus. Conclusion: Treatment for 24 weeks resulted in improvement in histopathologic featu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Akuta, Norio, Watanabe, Chizuru, Kawamura, Yusuke, Arase, Yasuji, Saitoh, Satoshi, Fujiyama, Shunichiro, Sezaki, Hitomi, Hosaka, Tetsuya, Kobayashi, Masahiro, Kobayashi, Mariko, Suzuki, Yoshiyuki, Suzuki, Fumitaka, Ikeda, Kenji, Kumada, Hiromitsu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5747031/ https://www.ncbi.nlm.nih.gov/pubmed/29404432 http://dx.doi.org/10.1002/hep4.1019

Ejemplares similares

SGLT2 Inhibitor Treatment Outcome in Nonalcoholic Fatty Liver Disease Complicated with Diabetes Mellitus: The Long-term Effects on Clinical Features and Liver Histopathology
por: Akuta, Norio, et al.
Publicado: (2020)

Analysis of association between circulating miR-122 and histopathological features of nonalcoholic fatty liver disease in patients free of hepatocellular carcinoma
por: Akuta, Norio, et al.
Publicado: (2016)

Simple Predictive Markers and Clinicopathological Features of Primary Liver Cancer following HCV Clearance with Direct-Acting Antivirals
por: Akuta, Norio, et al.
Publicado: (2023)

Hepatocellular carcinoma is the most common liver-related complication in patients with histopathologically-confirmed NAFLD in Japan
por: Akuta, Norio, et al.
Publicado: (2018)

Predictors of Insulin Secretion in Japanese Patients with Histopathologically-confirmed Non-alcoholic Fatty Liver Disease
por: Akuta, Norio, et al.
Publicado: (2019)

Serum TERT C228T is an important predictor of non-viral liver cancer with fatty liver disease
por: Akuta, Norio, et al.
Publicado: (2022)

Portal vein thrombosis in liver cirrhosis: incidence, management, and outcome
por: Fujiyama, Shunichiro, et al.
Publicado: (2017)

Relationships between Genetic Variations of PNPLA3, TM6SF2 and Histological Features of Nonalcoholic Fatty Liver Disease in Japan
por: Akuta, Norio, et al.
Publicado: (2016)

New Discriminant Method for Identifying the Aggressive Disease Phenotype of Non-alcoholic Fatty Liver Disease
por: Kawamura, Yusuke, et al.
Publicado: (2017)

Non-invasive predictors of prognosis of Asian patients with histopathologically-confirmed lean nonalcoholic fatty liver disease
por: Iritani, Soichi, et al.
Publicado: (2020)

Circulating MicroRNA‐122 and Fibrosis Stage Predict Mortality of Japanese Patients With Histopathologically Confirmed NAFLD
por: Akuta, Norio, et al.
Publicado: (2019)

Mortality rates and risk factors in 1412 Japanese patients with decompensated hepatitis C virus-related cirrhosis: a retrospective long-term cohort study
por: Fujiyama, Shunichiro, et al.
Publicado: (2021)

Ultrasensitive Assay for Hepatitis B Core‐Related Antigen Predicts Hepatocellular Carcinoma Incidences During Entecavir
por: Hosaka, Tetsuya, et al.
Publicado: (2021)

PNPLA3 genotype and fibrosis-4 index predict cardiovascular diseases of Japanese patients with histopathologically-confirmed NAFLD
por: Akuta, Norio, et al.
Publicado: (2021)

A Patient with HCV Infection and a Sustained Virological Response to Direct-acting Antiviral Treatment Who Developed Inclusion Body Myositis
por: Kuwano, Toru, et al.
Publicado: (2018)

Fulminant Hepatitis due to de novo Hepatitis B after Cord Blood Transplantation Rescued by Medical Treatment
por: Sano, Tomoya, et al.
Publicado: (2020)

Role of NS5A-L31/Y93 Double Wild-type in Failure of Glecaprevir/Pibrentasvir Double Therapy in Two Patients with a History of Direct-acting Antiviral Agent Failure: An Ultra-deep Sequencing Analysis
por: Sano, Tomoya, et al.
Publicado: (2019)

Favorable impact of long‐term SGLT2 inhibitor for NAFLD complicated by diabetes mellitus: A 5‐year follow‐up study
por: Akuta, Norio, et al.
Publicado: (2022)

The Lack of Hepatocyte Steatosis in Adult-onset Type II Citrullinemia Patients as Assessed by 7-year Interval Paired Biopsies
por: Suzuki, Hiroyuki, et al.
Publicado: (2019)

Poorly Differentiated Hepatocellular Carcinoma in a Low-risk Patient with an Otherwise Normal Liver
por: Ogasawara, Nobuhiko, et al.
Publicado: (2019)

Diagnosis and Resection Treatment of Triplet Hepatocellular Carcinomas with a non-B non-C Background in a Middle Aged Man over a Period of 6-years
por: Kajiwara, Akira, et al.
Publicado: (2020)

Long-term effects of peginterferon alfa-2a therapy in Japanese patients with chronic hepatitis B virus infection
por: Masaki, Keiichi, et al.
Publicado: (2015)

Virologic breakthrough in a patient with chronic hepatitis B by combination treatment with tenofovir disoproxil fumarate and entecavir
por: Suzuki, Fumitaka, et al.
Publicado: (2014)

Transcatheter Arterial Chemotherapy with Miriplatin for Hepatocellular Carcinoma Patients with Chronic Renal Failure: Report of Three Cases
por: Imai, Norihiro, et al.
Publicado: (2013)

Efficacy and Safety of Ramucirumab in Patients with Unresectable Hepatocellular Carcinoma with Progression after Treatment with Lenvatinib
por: Kasuya, Kayoko, et al.
Publicado: (2020)

Changes in the Mean Intrahepatic Target Computed Tomography Attenuation Value During Treatment May Be a Useful New Predictor of the Post-progression Survival Associated with Lenvatinib Treatment
por: Muraishi, Nozomu, et al.
Publicado: (2021)

What Is the Most Effective Drug Delivery System for Cisplatin during the Treatment of Hepatic Tumors with Single-Session Transcatheter Chemotherapy? A Pilot Study
por: Kawamura, Yusuke, et al.
Publicado: (2013)

New discriminant score to predict the fibrotic stage of non-alcoholic steatohepatitis in Japan
por: Kawamura, Yusuke, et al.
Publicado: (2015)

The Impact of Lenvatinib on Tumor Blood Vessel Shrinkage of Hepatocellular Carcinoma during Treatment: An Imaging-Based Analysis
por: Muraishi, Nozomu, et al.
Publicado: (2023)

Efficacy of the Combination of Systemic Sequential Therapy and Locoregional Therapy in the Long-Term Survival of Patients with BCLC Stage C Hepatocellular Carcinoma
por: Kawamura, Yusuke, et al.
Publicado: (2023)

Cholangiolocellular Carcinoma in a Young Patient Who Showed Sustained Virological Response after Treatment for Hepatitis C Virus Infection
por: Osawa, Mitsutaka, et al.
Publicado: (2017)

Two Cases of Advanced Hepatocellular Carcinoma Who Responded Well to the Combination of Durvalumab Plus Tremelimumab After Disease Progression During Atezolizumab Plus Bevacizumab Therapy Under Bevacizumab Withdrawal
por: Kawamura, Yusuke, et al.
Publicado: (2023)

Noninvasive Assessment of Advanced Fibrosis Based on Hepatic Volume in Patients with Nonalcoholic Fatty Liver Disease
por: Hayashi, Tatsuya, et al.
Publicado: (2017)

Rise of sodium-glucose cotransporter 2 inhibitors in the management of nonalcoholic fatty liver disease
por: Dokmak, Amr, et al.
Publicado: (2019)

Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020
por: Tokushige, Katsutoshi, et al.
Publicado: (2021)

Inhibition of sodium glucose cotransporter 2 (SGLT2) delays liver fibrosis in a medaka model of nonalcoholic steatohepatitis (NASH)
por: Goto, Ryo, et al.
Publicado: (2019)

Surveillance of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease
por: Sumida, Yoshio, et al.
Publicado: (2020)

Progression of liver fibrosis is associated with non‐liver‐related mortality in patients with nonalcoholic fatty liver disease
por: Tada, Toshifumi, et al.
Publicado: (2017)

Impact of Sodium Glucose Cotransporter 2 Inhibitors on Nonalcoholic Fatty Liver Disease Complicated by Diabetes Mellitus
por: Zhang, Enxiang, et al.
Publicado: (2021)

Nineteen-year prognosis in Japanese patients with biopsy-proven nonalcoholic fatty liver disease: Lean versus overweight patients
por: Hirose, Shunji, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1htro6u1gmnumfh88aetd6uh5q